The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASCO 2017 | Lenalidomide and ibrutinib: do they have a future in treating CLL?
Nitin Jain, MD, from the University of Texas MD Anderson Cancer Center, Houston, TX, talks to us about the implications of the positive results from clinical trials on treating chronic lymphocytic leukemia (CLL) with lenalidomide in addition to fludarabine and rituximab (NCT00860457), presented at the American Society of Oncology (ASCO) 2017 Annual Meeting in Chicago, IL. The future of treating CLL with combination regimens including ibrutinib (NCT02301156), and the need to re-design clinical trials to consider the complications of Richter’s Transformation in CLL is also discussed here.
